Close Menu

NEW YORK – Quest Diagnostics said Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a technique that speeds the extraction of viral RNA from patient samples.

The Secaucus, New Jersey-based company said it believes the technique, which it plans to run at six of its facilities, will let it expand its molecular SARS-CoV-2 testing capacity. Quest can currently run 135,000 molecular SARS-CoV-2 tests per day and expects the new method to boost that figure by 35,000 tests per day.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.